Clinical trials: Fibrotic Lung Disease
Obstructive Airway Disease
Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture
The purpose of this study is to evaluate the efficacy and safety of four interventional pulmonology techniques for the treatment of fibrotic central airway stricture.
- Trial name
- NCT02287389
- Testing
- balloon dilation, cryotherapy, spiculiform electrosurgery
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tang-Du Hospital
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Greater than 50% of lung transplant recipients show signs of chronic lung allograft dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are lacking.
- Trial name
- NCT03473340
- Testing
- Pirfenidone Capsule
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Michigan
Interstitial Lung Disease
Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
Patients are being offered participation in this pirfenidone trial because They have been diagnosed with fibrotic hypersensitivity pneumonitis (FHP), a type of interstitial lung disease (ILD).
- Trial name
- NCT02958917
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Evans Fernandez Perez
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Trial name
- TETON-OLE (NCT04905693)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 192 sites in United States, Argentina and 16 more
- Volunteers
- 1,850 people
- Sponsor
- United Therapeutics
Pulmonary Fibrosis, Pulmonary Hypertension
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's…
- Trial name
- NCT05356052
- Testing
- INOpulse
- Sponsor
- Bellerophon
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
Fibrotic Interstitial Lung Disease
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease
Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease.
- Trial name
- NCT00415272
- Testing
- Pulmonary Rehabilitation
- Where
- United States
- Sponsor
- University of California, San Francisco
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Post-COVID-19 Syndrome, Lung Fibrosis
Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis
In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.
- Trial name
- NCT05648734
- Testing
- Corticosteroids alone, Corticosteroids + Colchicine, Corticosteroids + Pirfenidone
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University
Covid-19
The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients
A randomized controlled trial (RCT) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients.
- Trial name
- HKCOVID19Res (NCT04799743)
- Testing
- Resveratrol
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hong Kong Baptist University
Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if…
- Trial name
- FIBROPOC (NCT06714123)
- Testing
- Senicapoc
- Where
- 5 sites in Denmark, Estonia and 1 more
- Volunteers
- 140 people
- Sponsor
- Vejle Hospital
Hypersensitivity Pneumonitis, Extrinsic Allergic Alveolitis
Pulmonary Rehabilitation in Patients With Chronic Fibrotic Hypersensitivity Pneumonitis
The aim is to evaluate exercise capacity, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, physical activity level, quality of life, fatigue, dyspnea, anxiety, depression and…
- Trial name
- NCT04561479
- Testing
- Pulmonary Rehabilitation, Alternative Exercises
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary…
- Trial name
- REBUILD (NCT03267108)
- Testing
- INOpulse®, Open Label Extension
- Where
- 64 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Bellerophon Pulse Technologies
Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia
Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the lungs into the blood.
- Conditions
- Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Hypoxemia
- Trial name
- NCT07512687
- Testing
- Portable Oxygen Concentrator, Portable compressed oxygen D-tanks, No ambulatory oxygen therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- State University of New York at Buffalo
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
IPF, Fibrotic Lung Disease
Prognostic Score Comparison in IPF and HP
The goal of this retrospective observational study is to evaluate and compare the prognostic value of GAP, ILD-GAP, and CPI scoring systems in patients diagnosed with interstitial lung diseases (ILDs), specifically Idiopathic…
- Conditions
- IPF, Fibrotic Lung Disease, Hypersensitivity Pneumonitis, Interstitial Lung Disease (ILD)
- Trial name
- NCT07169253
- Testing
- GAP Index, ILD-GAP Index, Composite Physiologic Index (CPI)
- Where
- Turkey (Türkiye)
- Volunteers
- 143 people
- Sponsor
- Saglik Bilimleri Universitesi
Sarcoidosis, Pulmonary
Pirfenidone for Progressive Fibrotic Sarcoidosis
Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis
- Trial name
- PirFS (NCT03260556)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Pulmonary Fibrosis
An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology
The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary fibrosis will be evaluated.
- Trial name
- I-FILE (NCT04304898)
- Testing
- Home spirometry
- Where
- 2 sites in Netherlands
- Volunteers
- 700 people
- Sponsor
- Erasmus Medical Center